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ABSTRACT 
The objective of the study is to formulate the emulgel of Doxycycline hyclate and Eugenol for sustained or controlled release gel for oral care. 
Doxycycline hyclate is an antibiotic which belongs to chemical class tetracyclines and widely used in treatment of oral care bacterial infections. 
Eugenol oil is extracted from the clove and act as good analgesic and anti-inflammatory. The combination of Doxycycline hyclate and eugenol 
can be formulated for better oral care treatment. The compatibility study performed of drug and drug-polymer by IR spectra indicates good 
compatibility. The simple manufacturing method is employed as hot emulsification. The formulations were evaluated for description, pH, 
viscosity, spreadability, extrudability, % drug content and content uniformity. Optimized formulations were evaluated for In-vitro release, 
antibacterial activity, and stability study. Formulated formulations were complying with all the evaluation parameters. The highest drug release 
found with the formulation OFEG 01 and OFEG 06. The formulations OFEG 06 is the most stable formulation in stability at acc elerated, 
intermediate and room temperature storage condition for 3months.  
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INTRODUCTION 
Doxycycline hyclate belongs to the class of tetracycline 
antibiotics which is widely to treat adult gum disease 
(periodontitis). Doxycycline is broad spectrum antibacterial 
drug widely effective in treatment of gram positive as well as 
gram negative bacteria. Doxycycline is indicated for use in 
respiratory tract infections caused by Mycoplasma 
neumoniae, Haemophilus influenzae, Streptococcus 
pneumoniae, Legionella spp., or lebsiella spp. It is also used 
for prophylaxis of malaria. 1-4 
Clove and clove oil are used anciently in Ayurveda as 
analgesic and anti-inflammatory. Eugenol is major 
component of clove oil. Eugenol is used in perfumeries, 
flavourings, essential oils and in medicine as an analgesic, 
anti-inflammatory, antimicrobial, and aesthetic. Eugenol is a 
member of the phenylpropanoids class of chemical 
compounds. It is a clear to pale yellow oily liquid extracted 
from certain essential oils especially from clove oil, nutmeg, 
cinnamon, basil and bay leaf.5-8 
Periodontitis is disease condition which is characterized by 
inflammation of the gums and supporting structures of the 
teeth. Periodontitis is most widely occurring human disease. 
Oral drug delivery is used for sustained release and 
controlled release drug for better absorption and therapeutic 
efficacy. The sustained and controlled release of doxycycline 
and eugenol formulation for local application can be 
formulated for better treatment for longer duration. The 
hydrophobic formulation will remain intact in mouth for 
longer time due to less aqueous solubility. 9-12 
Combination of Doxycycline and eugenol will be the good 
therapeutic combination in same dosage form for oral care. 
Doxycycline will help in treatment of periodontitis and 
eugenol will act as an analgesic, anti-inflammatory, 
antimicrobial, and aesthetic. The Doxycycline will be in 
aqueous layer of formulation and Eugenol will be in oil 
phase.   
MATERIAL AND METHOD 
Material: 
Doxycycline hyclate (Changzhou Pharmaceutical Factory, 
China), Eugenol (Symrise, USA), Isopropyl Myristate (BASF 
India), Mineral Oil (Croda, India),  Butylatedhydroxytoluene 
(Merck Germany) Sorbitan Stearate (Croda, India), 
Polysorbate 20 (Seppic, France), Emulsifying wax (Connel 
brothers, India), Cetyl alcohol (Fine organics, India), 
Carbopol 974P (Lubrizol, India),  Disodium EDTA (Merck, 
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Germany), Benzyl alcohol (Avantor, India) and Purified 
water (inhouse).  
Method: 
Compatibility study by IR: 
The IR spectra of previously dried samples of solid excipients 
were recorded by potassium bromide dispersion technique 
using 2-3 mg sample of each polymer as described for solids. 
For lecithin, the IR absorption spectrum was recorded with 
FTIR instrument (with diffused reflectance) in liquid sample 
cell.13-15 
Preparation of Emulgel: 
Oil Phase: Melt and mix Isopropyl myristate, Mineral oil, 
Sorbitan stearate, Butyl atedhydroxy toulene, Sorbitan 
Stearate, Emulsifying wax, Cetyl alcohol and Eugenol under 
stirring. Maintain the temperature at 60°C. Aqueous Phase: 
Dissolve Disodium EDTA in mixture of Purified water and 
Polysorbate 20 under stirring. Drug Phase: Dissolve 
Doxycycline hyclate in Aqueous phase. Heat and Maintain the 
temperature at 60°C. Emulsification: Homogenise the oil 
phase and drug phase for 10min at temperature at 60°C. 
Cooling under Homogenization: Cool the bulk under 
homogenization till temperature of bulk reached to 32-35°C. 
Mixing: Mix the bulk under stirring till temperature of the 
bulk reaches 28-32°C. 16-18 
 
Table 1: Formulation composition for Emulgel 
Sr. No. Ingredients 
Formulation Number 
EMG 01 EMG 02 EMG 03 EMG 04 EMG 05 EMG 06 
1 Doxycycline hyclate 2.00 2.00 2.00 2.00 2.00 2.00 
2 Eugenol 2.00 2.00 2.00 2.00 2.00 2.00 
3 Isopropyl Myristate 10.00 10.00 10.00 10.00 10.00 10.00 
4 Mineral Oil 10.00 10.00 10.00 10.00 10.00 10.00 
5 Butylatedhydroxytoluene 0.10 0.10 0.10 0.10 0.10 0.10 
6 Sorbitan Stearate 1.00 2.00 3.00 1.00 1.00 1.00 
7 Polysorbate 20 3.00 2.00 1.00 3.00 3.00 3.00 
8 Emulsifying wax 5.00 5.00 5.00 5.00 6.00 7.00 
9 Cetyl alcohol 5.00 5.00 5.00 7.00 6.00 5.00 
10 Carbopol 974P 0.50 0.50 0.50 0.50 0.50 0.50 
11 Disodium EDTA 0.10 0.10 0.10 0.10 0.10 0.10 
12 Benzyl alcohol 1.00 1.00 1.00 1.00 1.00 1.00 
13 Purified water 60.30 60.30 60.30 58.30 58.30 58.30 
 
Evaluation Parameter: 
The emulgel formulation will be evaluated for the physical, 
chemical and microbiological properties. Physical properties 
such as color, appearance, phase separation, homogeneity, 
smell, taste, pH, viscosity, spreadability and extrudability. 
Chemical properties such as % drug content and content 
uniformity. Microbiological properties such as microbial 
limit test for aerobic and anaerobic bacterial strains. 19-21 
Description: 
The formulated formulations were evaluated for colour, 
appearance, homogeneity, phase separation, smell and taste. 
22-23 
pH: 
pH of the formulation was measured with digital pH meter. 
The formulation was diluted with purified water to make 
10% Aqueous solution. The solution was made in triplicate 
and was measured. Mean of all the formulation results were 
recorded. 24-25 
Viscosity: 
The Viscosity of the formulation were measured by cone and 
plate Brookfield viscometer, model Cap 2000+. The sample 
of 100mg volume approximately were added on plate of 
viscometer. The method was loaded of 100rpm for 1min at 
temperature 30°C. The samples were run for three times and 
average of all three results were recorded. 26-28 
Spreadability: 
The spreadability of the formulations were measured by the 
spreading diameter of 1 g of formulations between 2 
horizontal glass plates after one minute. The standard 
weight applied to the upper plate was 25 g. Each formulation 
was measured in triplicates.29-32 
Extrudability: 
The all formulated formulations were filled laminated 
aluminium tube. The tubes were sealed with the help of 
laminated tube sealing machine by applying heat at 
temperature 70-80°C. The measured quantity of bulk is filled 
in each tube laminated aluminium tube. The filled tube was 
placed between two glass slides and clamped together. A 
specified quantity of fixed weight (500g) kept on glass slides 
and then cap of the tube was opened. The amount of bulk 
formulation was collected and weighed. The % of bulk 
formulation extruded was calculated and grades are allotted 
(+++ Excellent, ++Very Good, +Good). 33-36 
% Drug Content (Assay): 
The emulgel formulation containing 50 mg of Doxycycline 
hyclate and 12 mg of eugenol was dissolved in 25 ml of 
methanol (AR). The solution was sonicated for 15 minutes to 
complete the dissolution of the drug. The solution was 
filtered using Whatman filter paper (No. 41) and final 
volume was made up to 100 ml using distilled water. 
Appropriate dilutions were made using distilled water to 
give the solutions containing 50 μg/ml of Doxycycline 
Shelke et al                                                                                                              Journal of Drug Delivery & Therapeutics. 2019; 9(3):447-454 
ISSN: 2250-1177                                                                                  [449]                                                                                 CODEN (USA): JDDTAO 
hyclate and 12 μg/ml of Eugenol (n=3). The absorbances of 
these solutions were recorded at 354.0 nm (λ max) for 
Doxycycline hyclate and 280 nm (λ max) for Eugenol by UV 
spectrophotometer in spectrum mode. % Drug content of 
the solution was calculated. 37-40 
In-vitro Evaluation: 
The in vitro drug release study from the gel formulations 
was studied using a modified USP paddle method on 
Modified USP tablet dissolution test apparatus I. A glass 
cylinder (2.5 cm diameter), with a cellophane membrane 
(M.wt. cutoff 12,000) tied to one end, was attached to the 
metallic drive shaft of the dissolution apparatus and 
immersed in 250 of saline phosphate buffer pH 7.4 
maintained at temperature of 37 0 C. An accurately 
measured volume of formulations (1gm), was transferred to 
the glass tube. The shaft could rotate at constant speed of 
100 rpm. Aliquots of 5 ml were withdrawn at regular time 
intervals of 30 minutes for 8 hours, at 24 hours and at 48 
hours and replaced by an equal volume of fresh buffer. The 
drug content in the withdrawn samples were analysed UV 
spectrophotometrically at λmax of 354 nm and 280 nm for 
Doxycycline hyclate and Eugenol respectively. The 
concentration of Doxycycline hyclate and Eugenol in samples 
was determined from a calibration curve. 41-45 
Content Uniformity 
The formulation filled in 30g aluminium laminated tube and 
samples were analysed from Top, Middle and Bottom for the 
% drug content. The samples were analysed in duplicate and 
mean is recorded. The mean and standard deviation 
calculated for top, middle and bottom readings. 46-48  
Microbial Limit Test: 
The microbial limit test was performed as per the USP test. 
The test performed for anaerobic and aerobic bacterial 
count. 49-51 
Antimicrobial testing 
The optimized formulation was studied for Zone of 
inhibition by cup plate diffusion method. Staphylococcus 
aureus was incubated in Nutrient agar medium for 24 hours 
under aerobic conditions. 52-54 
The cup plate diffusion method involves sterilization of Petri 
plates, seeding of medium, inoculation and incubation. The 
plates were sterilized in autoclave. The nutrient broth for 
each bacterial agar was prepared in volumetric flask and 
sterilized by autoclaving. Molten agar (20ml) was poured in 
each Petri plate. The Petri plates were cooled up to 40°C and 
kept solidifying. Standard cultures of microbes were poured 
on top of the agar in the plates. After solidifying, wells of 
8mm were bored aseptically using sterile cork borer. The 
agar plugs were taken out carefully so as not to disturb the 
surrounding medium. The holes were filled with 0.1ml 
different gel formulations and drug solution. The plates were 
kept in an incubator at 37°C for specified time. After this 
Petri plates were observed for the antibacterial activity by 
measuring the zone of inhibition using scale. 
RESULTS AND DISCUSSIONS 
Compatibility study by IR: 
The IR Spectra shows that the functional groups of 
Doxycycline hyclate and Eugenol were intact in mixture of 
Doxycycline hyclate and Eugenol, Doxycycline hyclate and 
polymer, and eugenol and polymer. The Doxycycline hyclate 
and Eugenol are compatible with each other as well as with 
polymers. 
 
 
Figure 1: IR spectrum of Doxycycline hyclate 
 
Figure 2: IR spectrum of Eugenol 
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Figure 3: IR spectrum of Doxycycline hyclate and Eugenol 
 
Figure 4: IR spectrum of physical mixture of Doxycycline hyclate and polymers 
 
Figure 5: IR spectrum of physical mixture of Eugenol and polymers 
Evaluation Parameter: 
Description: 
The observations were recorded for colour, appearance, homogeneity, phase separation, smell and taste in Table 2. Description 
of the formulation is like white smooth homogenous cream without phase separation with acceptable smell and taste.  
Table 2: Results for the description of the formulations 
Batch No. Colour Appearance Homogeneity 
Phase 
Separation 
Smell Taste 
OFEG 01 White Smooth shiny Yes No Acceptable Acceptable 
OFEG 02 White Smooth shiny Yes Yes Acceptable Acceptable 
OFEG 03 White Smooth shiny Yes Yes Acceptable Acceptable 
OFEG 04 White Smooth shiny Yes No Acceptable Acceptable 
OFEG 05 White Smooth shiny Yes No Acceptable Acceptable 
OFEG 06 White Smooth shiny Yes No Acceptable Acceptable 
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pH: 
The pH of the all the formulations were stable and in range of 6.0 to 7.0. pH of the final formulation adjusted with Sodium 
hydroxide solution. The results are tabulated in table 3. 
Table 3: Results for the pH, Viscosity, spreadability, extrudability and % drug content 
Batch No. pH Viscosity Spreadability  Extrudability % Drug content 
OFEG 01 6.50 4.56 14.89 +++ 98.9 
OFEG 02 6.67 4.13 15.11 ++ 86.8 
OFEG 03 6.89 4.66 14.97 ++ 90.6 
OFEG 04 6.45 6.67 12.67 +++ 99.6 
OFEG 05 6.47 6.01 13.56 +++ 98.7 
OFEG 06 6.52 5.89 14.45 +++ 97.7 
 
Viscosity: 
The viscosity of the formulation was found in the range of 
4.13-6.67 Cps. The results are tabulated in table 3. The 
viscosity of the formulation is dependant on the 
concentration polymer and the concentration of solid 
emulsifiers in formulation. The increase in the polymer 
concentration and solid emulsifiers concentration viscosity 
of the formulation increases. The solid emulsifiers are also 
contributing to the formation of viscosity.  
Spreadability: 
The spreadability of the formulation was found in the range 
of 12.67-15.11 g/cm-1. The results are tabulated in table 3. 
The spreadability of the formulation is dependant on the 
viscosity of the formulation. Higher the viscosity of the 
formulation, lower will be the spreadability of the 
formulation.  
Extrudability: 
The extrudability of the formulation will be dependant on 
the viscosity of the formulation and smooth texture of the 
formulations. The extrudability of the formulation was 
acceptable. The results were tabulated in the Table 3. (+++ 
Excellent, ++Very Good, +Good). 
% Drug Content (Assay): 
The drug content of the formulations was found in the range 
86.8-99.6%. The % drug content of all the formulation were 
acceptable and tabulated in table 3. The assay of the 
formulation OFEG 02 and OFEG 03 was found to be less, this 
may be due to separation of phases which lead to show 
variation in assay.  
Content Uniformity 
The content uniformity of all the formulations complies with 
USP specifications except formulations OFEG 02 and OFEG 
03. The results are tabulated in Table 4. The container 
uniformity results for the formulation batch number OFEG 
02 and 03 fails to comply with the specification. This may be 
due to phase separation of the formulation.  
 
Table 4: Results for the content uniformity and microbial limit test 
Batch No. 
Content Uniformity 
Microbial Limit test 
Top Middle Bottom Mean SD 
OFEG 01 98.7 99.0 98.6 98.8 0.2 Complies as per USP 
OFEG 02 85.8 105.5 80.5 90.6 13.2 Complies as per USP 
OFEG 03 88.6 91.5 109.7 96.6 11.4 Complies as per USP 
OFEG 04 99.3 99.1 98.8 99.1 0.3 Complies as per USP 
OFEG 05 98.6 98.5 98.3 98.5 0.2 Complies as per USP 
OFEG 06 97.9 98.2 98.3 98.1 0.2 Complies as per USP 
 
In-vitro Evaluation: 
The invitro release of the Doxycycline was found the range 
of 63-77% after 48 hrs. The formulation OFEG 01 has 
highest drug release amongst all he formulation. This may be 
due to low viscosity of the formulation. The formulation 
OFEG 02 has much slower drug release than the other 
formulation. The drug release pattern of OFEG 06 and OFEG 
01 is same but the OFEG 01 has higher drug release than the 
OFEG 06. The results are tabulated in Table 5 and 
graphically represented in figure 6.  
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Table 5: Results for the In-vitro release test for Doxycycline. 
Time (min) 
Doxycycline hyclate Eugenol 
OFEG 01 OFEG 04 OFEG 06 OFEG 01 OFEG 06 
0 0.000 0.000 0.000 0.000 0.000 
30 13.289±0.81 7.194±0.13 10.373±0.11 9.352±0.04 8.482±0.04 
60 19.021±0.13 11.049±0.26 17.805±0.20 15.358±0.04 13.561±0.11 
90 25.504±0.05 16.651±0.21 23.656±0.35 20.746±0.03 18.782±0.05 
120 30.460±0.15 17.914±0.12 28.463±0.40 26.342±0.05 24.431±0.06 
150 35.000±0.12 19.491±0.24 34.384±0.31 31.587±0.05 29.228±0.02 
180 39.699±0.21 23.879±0.23 38.383±0.11 37.203±0.05 36.944±0.18 
210 43.971±0.65 27.382±0.16 42.718±0.05 42.580±0.04 40.339±0.16 
240 48.727±0.17 32.332±0.17 46.588±0.29 47.529±0.04 45.670±0.14 
270 52.191±0.08 37.448±0.28 50.496±0.23 51.947±0.06 49.921±0.22 
300 56.834±0.00 35.325±0.22 53.559±0.30 55.755±0.08 53.782±0.25 
330 60.994±0.32 40.789±0.21 57.167±0.33 58.036±0.09 56.626±0.19 
360 63.883±1.52 46.772±0.32 61.925±0.29 60.067±0.10 58.041±0.23 
390 66.705±1.12 51.975±0.18 64.637±0.25 63.192±0.10 61.445±0.19 
420 70.028±1.09 54.744±0.07 67.341±0.27 66.500±0.09 64.746±0.32 
450 74.535±0.41 59.058±0.07 71.946±0.28 69.318±0.08 67.625±0.33 
480 77.916±0.71 63.968±0.09 74.529±0.22 72.453±0.08 70.102±0.25 
 
 
Figure 6: Comparative In-vitro drug release profile Doxycycline  
 
Figure 7: Comparative In-vitro drug release profile Eugenol 
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Antimicrobial testing 
The zone of inhibition (ZOI) Formulations OFEG 01, OFEG 04 
and OFEG 06 were found in range of 3.8-4.5. The results are 
tabulated in Table 6. The ZOI was found highest for 
formulation OFEG 01, this may be due to highest drug 
release from the formulation. The higher drug release may 
be due to low viscosity of the formulation. 
 
Table 6: Results for the Antimicrobial testing. 
Batch No. OFEG 01 OFEG 02 OFEG 03 OFEG 04 OFEG 05 OFEG 06 
Zone of Inhibition (cm) 4.50 4.25 4.29 3.89 3.75 4.35 
  
CONCLUSION 
The emulgel formulation can be formulated with the 
composition of Doxycycline hyclate, Eugenol, Isopropyl 
Myristate, Mineral Oil, Butylatedhydroxytoluene, Sorbitan 
Stearate, Polysorbate 20, Emulsifying wax, Cetyl alcohol, 
Carbopol 974P, Disodium EDTA, Benzyl alcohol, and Purified 
water. The doxycycline and eugenol are compatible with 
each other as well as polymer. The formulations have good 
stability and complies with the evaluation parameter except 
formulations OFEG 02 and 03. The invitro release study has 
shown that formulation OFEG 01 and OFEG 06 has similar 
pattern of drug release but formulation OFEG 04 has slower 
drug release. The formulation OFEG 01 and 06 has similar 
antimicrobial efficacy on nutrient media. The combination of 
Doxycycline hyclate and Eugenol has good antibacterial 
activity and expected to have better therapeutic efficacy. The 
formulation OFEG 06 has better stability at accelerated 
storage condition for 3Months.  
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